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PRO evidence is paramount. Adoption of PRO data by national and international can-
cer guidelines is key for centralized markets. Literature review findings corroborated 
with payer interviews indicated that inclusion of PRO data for crizotinib was crucial 
to achieving a price premium in Germany, with additional benefit based on PRO data 
on symptoms and quality of life. ConClusions: There is growing recognition that 
the patient perspective is important in market access decision making in central-
ized markets and PRO data can be a key differentiator among therapeutic options.
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objeCtives: The European Union Directive (2011/24/EU) requires member states 
to establish pathways that enable patients to receive reimbursed treatment in 
another European Union country. These cross-border access pathways are becom-
ing increasingly relevant for highly specialised medical technologies such as proton 
beam therapy and gene therapy, which are delivered by only a handful of provid-
ers across Europe. The objectives of our study were to understand how approvals 
for reimbursed cross-border treatments in the context of highly specialised treat-
ments work in Germany, and to identify any barriers and practical steps to overcome 
these. Methods: We have investigated the case-by-case access decision pathway for 
German patients to receive highly specialised treatments in another country using 
secondary research, and awareness surveys with Health Care Practitioners. Results: 
We found the biggest barrier for cross-border treatment access are delays in the 
case-by-case approval process caused by (a) low awareness of cross-border access 
pathways amongst Health Care Practitioners, (b) the lack of well-defined guidelines 
on how to make the case for medical need, and (c) case-by-case reimbursement 
negotiations between the sickness fund and the treatment provider in the other 
country. ConClusions: To overcome these barriers we suggest manufacturers 
and/or the provider of the highly specialised treatment to engage with the MDK 
(Medizinischer Dienst der Krankenkassen - Medical Service of Health Insurance) to 
define the requirements of the patient dossier, and to agree a checklist to bring a 
degree of objectivity in to medical need assessment. Additionally, we suggest work-
ing with the major sickness funds to negotiate a reimbursement rate, in advance 
of the first patient being identified for the treatment. Establishing these processes 
and making Health Care Practitioners aware of them would reduce approval times 
for German patients to access highly specialised treatments delivered in another 
EU member state.
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objeCtives: Within the German hospital landscape (in-patient), NUBs (Neue 
Untersuchungs- und Behandlungsmethoden) [new treatment and examination 
methods] represent a key method to achieve reimbursement for new, cost-intensive 
drugs, medical products or procedures. NUBs are paid on top of hospital budget and 
hence represent additional funding for hospitals. The objective of this analysis was 
to provide an overview on the proportion of drugs (vs. methods, medicinal prod-
ucts) and their respective indications for 2015 and compare these to the results 
of 2014. Methods: The German DRG database issued by the InEK (Institute for 
Hospital Remuneration System) is used to analyse NUB subgroups sorted according 
to key therapeutic indications for the years 2015 and 2014. Additionally the number 
of NUB 1 (positive status) products that went through the AMNOG process up to 
June 2015 is being analysed. Results: Out of 670 NUB submissions 159 (24%) are 
classified as drugs in 2015. Results for the year 2014 were 618 NUB submissions with 
133 (22%) drugs. The analysis also compares proportion of drugs in different NUB 
classification levels for 2015 and 2014 (NUB 1-4). Leading therapeutic areas are iden-
tified. Chances to grant a successfull NUB 1 status approval for drugs and procedures 
are examined. Out of 56 drugs that were given NUB 1 status, 29 (52%) had passed 
through AMNOG process until June 2015. 43 drugs with NUB status 1 and 24 (55%) 
that had passed the early benefit assessment by June 2014 (55%). ConClusions: 
Drug applications are more likely than procedures to be given NUB 1 status and 
thereby initiate reimbursement negotiations with the SHI. Results of 2015 confirm 
the findings for 2014. Oncology products showed the highest success rates in two 
consecutive years. Oncology products are often high priced therapies and use the 
NUB system to enter the G-DRG system for future reimbursement.
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objeCtives: Although AMNOG was introduced to reorganize the medicine prod-
ucts market, it is not applicable for vaccines. Immunization in Germany is organized 
de-centrally under the responsibility of the social health insurance. The aim of this 
study was to analyze the market access route and compare that to the AMNOG pro-
cess. Methods: The market access route was analyzed systematically and mapped 
the pathway by identifying key processes, stakeholders, applicable regulations and 
laws, pricing and negotiation setting and supply chain conditions. Results: Based 
on the results of the systematic analysis we could ascertain specifics for the vaccina-
tion market. The Standing Committee on Immunisation (STIKO) by the Robert Koch 
Institute decides regularly on vaccination recommendations. Vaccinations are obliga-
tory provisions of the SHIs and based on a regulation within with the G-BA defines 
details and requirements, type and scope. Further, SHIs can provide optional benefits 
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objeCtives: The economic evaluation of new medicines is substantial for allo-
cating the limited healthcare budgets. In Bulgaria, according to the legislation for 
pricing and reimbursement of medicinal products applied to be included in the 
Positive Drug List, pharmacoeconomic assessment shall be performed according 
to the criteria based on efficacy, therapeutic effectiveness, safety, and pharmaco-
economic parameters. However, until recently there were no detailed guidelines 
for applicants available and in April 2015 methodological recommendations were 
implemented. The objective of methodological recommendations is to achieve 
optimal assessment of candidate medicinal products applying for the PDL inclu-
sion. Methods: A working group of representatives from National Council for 
Pricing and Reimbursement of medicinal products, Bulgarian Drug Agency, and 
experts from academia developed a guideline, following the good practices of other 
countries to provide standardized approach to economic evaluation of medicinal 
products in Bulgaria. Results: The guideline is structured in five sections including 
requirements for provided data for efficacy, therapeutic effectiveness and safety, as 
well as pharmacoeconomic parameters. Applicants need to prepare their applica-
tions according to the requirements provided by these methodological recommen-
dations.There should be a clear and unambiguous conclusion about the benefits 
of the medicinal product, subject to evaluation over the existing alternatives, the 
clinical significance and its place in therapy. If there is an economic evaluations 
conducted with a candidate medicinal product for other health systems or pub-
lished by HTA agencies in Europe it is necessary to be provided with respective 
motives for positive or negative decision. ConClusions: The implemented phar-
macoeconomic guideline will facilitate the appraisal of medicinal products based 
on objective and transparent information which will allow the decision makers to 
justify the reimbursement of new medicinal products based on scientific evidences 
and available resources.
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objeCtives: Before biosimilars entered the market the decision making process 
for payers regarding generics was straightforward. As the active pharmaceutical 
ingredient was the same molecule, a cheaper generic version would always be 
more cost-effective than its original counterpart. This changed with the upcoming 
of biosimilars of erythropoiesis-stimulating agents. Several publications pointed 
to differences in effectiveness between original and generic versions. Therefore, 
a payer no longer could solely rely on price comparison, but had to factor the effi-
cacy difference when he was trying to limit drug expenditures. The question arose 
whether the efficacy gaps are only observed in erythropoetins or are general for all 
biologicals. Methods: We searched the scientific literature and the EMA database 
for comparative studies for all currently approved biosimilars in Europe. Data for the 
quantity needed to reach a given therapeutic effect, was extracted. Subsequently 
the prices from a German payers perspective were taken from official tariffs and 
applied to the price-efficacy-equation. Results: Until Q1/2015 19 biosimilars were 
granted market authorization in Europe. Analysis showed that erythropoetins are 
the only ones with relevant efficacy differences between originator and generic 
version. All other biosimilar agents were equivalent to the reference drug according 
to EMA standards. Price information was not available for three drugs currently not 
marketed in Germany. For all other drugs the prices of the generic versions were 
significantly below the originator version resulting in a better price-efficacy-ratio 
for the biosimilars. ConClusions: Except for erythropoetin biosimilars no differ-
ences in efficacy could be observed in the analyzed study data. Therefore it seems 
legitimate for payers to limit their view to the price in the price-efficacy-ratio when 
making reimbursement decisions regarding biosimilars.
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objeCtives: To understand how PRO data from clinical trials are utilized in market 
access decision making in oncology and other disease areas in markets with central-
ized healthcare systems. Methods: PubMed/MEDLINE, Embase, ISPOR databases, 
and regulatory and HTA websites for the EMA, the UK, France, and Germany were 
searched to identify PRO data included in regulatory and HTA submissions of four 
oncology drugs: bevacizumab, pemetrexed, sunitinib, and crizotinib. One-on-one 
interviews were conducted with 10 payers from different countries with centralized 
healthcare systems in 2014. An online assessment was conducted (December 8, 2014, 
to March 4, 2015) with 5 completed surveys (China, France, Germany, Taiwan, the UK) 
and 2 partially completed surveys (Australia and South Korea) by payers from the 
RTI Health Solutions Global Payer Advisory Panel. Results: Reviews of HTA and 
reimbursement decisions indicate that HTA bodies have varying levels of familiarity 
and confidence in PRO data. All 10 payers indicated that it is worthwhile to collect PRO 
data in clinical trials for oncology, particularly in phase 3 and postmarketing studies. 
Payers speculated that PRO data will increase in importance over the next 5-10 years 
and could be a key differentiator for new therapies. Payers offered little differentiation 
in the importance of PRO data by cancer type. Payers indicated that the quality of the 
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stand the advice patterns and reasoning behind its decision. Methods: Research 
was conducted using the SMC Advice Directory, of which section contains all SMC 
advice made. The advice published between January 1st 2012 and April 7th 2015 was 
examined. Variables collected include drug name, manufacturer, BNF category, sub-
category, status of orphan drug or/and end of life, submission type, resulting status 
and rationale behind the decision. Data were extracted and collated into one excel 
sheet for the further analysis. Results: During the time period examined, 120 sub-
missions have been made to the SMC. Among these 120 submissions, 46 submissions 
have been accepted for use within NHS Scotland for the indication requested, while 
43 have been accepted for restricted use and 31 have been not recommended. The 
following are the three types of drugs that have been most frequently submitted to 
the SMC for its review: cytotoxic drugs (20 submissions), those used in diabetes (12) 
and those affecting the immune response (10). ConClusions: There have been some 
interesting features of the SMC advice. Nevertheless, due to the small number of the 
advice published during the time period analysed, it is difficult to reach any statisti-
cally valid conclusion regarding its decision-making patterns.
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objeCtives: Pharmaceutical industry continues to grow and drug prices are a bur-
den for countries.Reference price system is assumed that such a practice concern-
ing medicines will lead to a decrease in medicine expenditures as medicine prices 
decrease.The purpose of this analysis is to determine the distribution of the discount 
of original medicines in ATC groups from the reimbursement agency perspective in 
Turkey. Methods: “Detailed Price List” data published on the website of the Ministry 
of Health and “Annex 4-A Funded Medicines List” data published by Social Security 
Institution(SSI) were used.The lists were merged using the Excel software and generic 
medicine including genericized original medicines with different pricing and pay-
ment conditions compared to original medicines with no generics and other specific 
medicines such as blood products,etc. and specific conditions such as medicines with 
no reimbursement were excluded.The analysis was made with a total of 568 original 
medicines with no generic.Ex-factory prices were used in the analysis. Results: The 
original drug distribution examination according to ATC1 groups showed that groups B 
and L had the highest number of original medicines with no generic with 16.55%.The 
price distribution examination according to ATC1 groups showed that the most expen-
sive original medicines with no generic were in group L with 27.31%.The examination 
of SSI discount rates according to ATC1 groups showed that original medicines in group 
S had the highest average discount rate with 46.1%.The ATC1 group with the sec-
ond highest average discount rate,41%,was not specified and identified to be original 
medicines in group M. ConClusions: In ATC1 group the original drugs distribution 
is mostly contains group B and L.The highest-priced original drugs are in ATC1 is in L 
group that is also expected in terms of the properties of L group.The highest discount 
rates are in group S however,the lowest price of original drugs are also in S group.
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objeCtives: Recently, the need for health services has increased gradually and the 
limitations in sources allocated for this area have been recognized. Moving from 
this fact, it has gained a supreme importance to determine what health programs 
or technologies will be given priority. According to Danzon (2001), arrangements 
towards controlling the expenses through price and profit controls, reimbursement 
methods and incentives have recently gained wide currency Methods: This pre-
sent study examines; along with the current situation in Turkey, pharmaceutical 
pricing methods, reimbursement methods and basic health indicators, within the 
scope of changing pharmaceutical policies, in Turkey, obtained results and effects 
of those results so far. Results: Upon the research conducted, it was founded that 
the pharmaceutical policies in Turkey has been effected medicines prices dramati-
cally last few years. Pricing and Reimbursement regulation changed several times 
and but public health expenditure hasn’t decreased. Access to healthcare was main 
factor of health expenditures. Rational drug use was another issue which is main 
aim to Turkish Authorities ConClusions: Although it is natural for Turkey to put 
restrictions on drugs budget to ensure sustainable drug financing, in order to main-
tain the existence of pharmaceutical industry and protect the patients’ access to 
medicines; it would be more favorable in the development of the industry that the 
expectations of the stakeholders in the industry are taken into account in the policy 
making process. This would also help the already supported R&D activities to be 
sustainable as well. The positive and negative aspects of Turkey’s offering the least 
expensive medicine should be examined. Whether being the country to supply the 
least expensive medicine is the correct objective or not in the international arena 
should seriously be discussed. It is recommended that how this situation affects 
Turkey’s image in the outer world should be scrutinized.
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objeCtives: The objective of the study was to determine what is necessary for the 
benefit/risk assessment and estimating the added value (HTAs evaluations) based 
on the experience of previously included innovative products in the Bulgarian posi-
tive list from 2013 till July 2015. Methods: Analysis based on publicly available 
according to their statutes for those vaccinations not defined as mandatory. Vaccines 
are generally to be prescribed by a physician and pharmacies have the obligation to 
provide permanent supply of specific vaccines. The vaccination is conducted by physi-
cians and public health offices. The MoH defines, if the costs of specific vaccinations 
have to be beard by the SHIs other can be provided at no cost by the public health 
offices. The general pricing regulations for pharmaceuticals are applicable as well for 
vaccines however exemptions e.g. of surcharges etc. exist for those defined as manda-
tory vaccinations. Additionally tenders are regular instruments for vaccination buying 
processes. Key differences to the AMNOG are varying stakeholders at different levels 
and responsibilities of those. Pricing might be more flexible with vaccinations even 
though that tenders might apply. ConClusions: The systematic analysis revealed a 
clear market access road map, stakeholder compass and important strategic implica-
tions for the processes along with key differences to the AMNOG.
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objeCtives: The study aimed to determine the differences between countries 
pharmaceutical prices for on-patent medicines using an EKS method Methods: 
The indices were developed using the Fisher Elteto, Koves, Szulc (EKS) method. EKS 
is widely used by the Organisation for Economic Co-operation and Development 
(OECD) but has not yet been applied to pharmaceutical prices. IMS MIDAS data 
was used to estimate prices and sales volumes. In order to construct the indices, 
the products needed to be defined as like. The definition of like in this study was 
based on molecules which are deemed to deliver equivalent health outcomes. The 
price indices were developed for countries with the highest uptake of on patent 
medicines. The analysis compares prices across 9 countries over the period from 
2010 to 2011 and included 27 molecules which were sold in each country for the 
period. Results: US prices were the highest at the end of the period, 1.57; followed 
by France 1.21; Austria 1.11; Australia 1.10; Sweden 1.04; Finland 1.01; The UK 0.94; 
Japan 0.89 and Germany 0.69. Only two countries recorded reasonable increases in 
prices over the period, the USA (4.5% per quarter) and Finland (1.5% per quarter). 
When the simple average of the molecule prices in the countries was compared 
against the EKS method some countries appear to have much higher pricies. In 
particular, Japanese simple average prices are higher with the country being ranked 
4th highest and only 8th on the EKS. Similarly Germany is ranked 6th on the simple 
average and 9th on the EKS. This suggests heavy a substitution effect in these coun-
tries whereby usage shifts to comparatively cheaper molecules. ConClusions: 
This is part of a very large exercise comparing international pharmaceutical prices. 
It also employs a more robust method than previous studies. The analysis shows 
US and French prices to be the highest for on-patent medicines.
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objeCtives: To identify key success factors, barriers, and associated risks with intro-
ducing tiered pricing, defined as non-uniform pricing across customer segments 
in a country within the selected markets to increase patient access. Methods: 
Review of publicly available information including health authority, WHO websites, 
along with peer reviewed journals and other scholarly publications. Primary input 
from fifteen (15) current payers and industry professionals (3 in each country) for 
validation and gap mitigation. Results: Argentina and Mexico have distinct pub-
lic and private-sector based markets with different price expectations. Columbia 
has a single payer, Entidades Promotoras de Salud (EPS), and citizens with private 
insurance are still required to use EPS. The Indonesian healthcare market is highly 
segmented and approximately half of the Indonesian population does not have 
health insurance. Price negotiations are performed at the provider level in both the 
private and public sectors. In Thailand the private health insurance market is small 
and used as supplementary insurance, and the public market is separated into three 
segments (universal “30-Baht” coverage, Social Security Scheme, and Civil Service 
Medical Benefits Scheme). The Civil Service Medical Benefits Scheme (CSMBS) is the 
highest purchaser of high priced oncologics followed by the Social Security Scheme 
(SSS) with the universal “30-Baht” coverage only covering older lower priced/generic 
oncology products. ConClusions: Within the selected markets, Argentina and 
Mexico are the two markets where tiered pricing is straight forward with the private 
and public markets managed independently of each other. The potential for tiered 
pricing in Thailand exists between the CSMBS and the SSS, but less likely to occur 
in the Universal system (30-Baht) or private markets. With Columbia being a single 
payer healthcare system, tiered pricing is non-existent. With provider level price 
negotiations in Indonesia, informal tiered pricing can be in place based on supply 
and demand forces that would influence volumes purchased.
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objeCtives: Given the limited resources and increasing healthcare expenditure, 
a number of countries have established their own health-technology-assessment 
(HTA) bodies. These HTA bodies carry out their own assessments of medicines to 
accept for use the newly licensed medicines that represent good value for money. 
In Scotland, the Scottish Medicines Consortium (SMC) is responsible for such role 
as it reviews information supplied by the manufacturers and provides advice to the 
National Health Service (NHS) in Scotland. The purpose of this research is to examine 
the SMC formal advice following its assessment of products in order to better under-
